• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

A study of survival in patients with stomach cancer treated by a combination of preoperative intra-arterial infusion therapy and surgery.

作者信息

Fujimoto S, Akao T, Itol B, Koshizuka I, Koyano K

出版信息

Cancer. 1976 Apr;37(4):1648-53. doi: 10.1002/1097-0142(197604)37:4<1648::aid-cncr2820370405>3.0.co;2-3.

DOI:10.1002/1097-0142(197604)37:4<1648::aid-cncr2820370405>3.0.co;2-3
PMID:1260682
Abstract

Since 1968, there have been 62 patients with stomach cancer seen in the First Department of Surgery of Chiba University. Treatment consisted of preoperative intra-arterial chemotherapy and surgery. The chemotherapy entailed continuous infusion for 15 to 20 hours. The survival rates were analyzed with particular emphasis on the degree of serosal invasion of the stomach. The overall survivals at the end of 3 years were 54.2% for the treated patients, and 37.1% for the controls: and at the end of 5 years, 33.3% of the treated patients were living as compared to 29.7% of the control patients. In patients without serosal invasion, the survival rates were higher for those treated than for the controls for the first 2 years. At the end of 3 years, the 39 patients treated for serosal invasion had a survival rate of 46.8% vs. 29% in the controls: and at 5 years, 32.2% of the treated patients vs. 23.7% in the controls. The survival rates for the treated patients with cancerous infiltration of other organs were about the same as those for the corresponding control patients.

摘要

相似文献

1
A study of survival in patients with stomach cancer treated by a combination of preoperative intra-arterial infusion therapy and surgery.
Cancer. 1976 Apr;37(4):1648-53. doi: 10.1002/1097-0142(197604)37:4<1648::aid-cncr2820370405>3.0.co;2-3.
2
[Preoperative cancer chemotherapy for gastric cancer].
Gan To Kagaku Ryoho. 1985 May;12(5):1010-8.
3
Role of surgery in the patients with stage I and II primary gastric lymphoma.手术在Ⅰ期和Ⅱ期原发性胃淋巴瘤患者中的作用。
Hepatogastroenterology. 2003 May-Jun;50(51):877-82.
4
Intraoperative hyperthermic intraperitoneal chemotherapy as adjuvant chemotherapy for advanced gastric cancer patients with serosal invasion.术中腹腔内热化疗作为伴有浆膜侵犯的进展期胃癌患者的辅助化疗。
J Chin Med Assoc. 2013 Aug;76(8):425-31. doi: 10.1016/j.jcma.2013.04.004. Epub 2013 Jun 22.
5
A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy with D2 plus para-aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002.一项多西他赛、顺铂和S-1术前化疗联合D2根治术加主动脉旁淋巴结清扫术治疗伴有广泛淋巴结转移的胃癌的II期研究:JCOG1002
Gastric Cancer. 2017 Mar;20(2):322-331. doi: 10.1007/s10120-016-0619-z. Epub 2016 Jun 14.
6
Development of a risk-scoring system to evaluate the serosal invasion for macroscopic serosal invasion positive gastric cancer patients.开发一种风险评分系统,以评估宏观浆膜浸润阳性胃癌患者的浆膜侵犯情况。
Eur J Surg Oncol. 2018 May;44(5):600-606. doi: 10.1016/j.ejso.2018.01.240. Epub 2018 Feb 3.
7
A pilot study of an individualized comprehensive treatment for advanced gastric cancer with para-aortic lymph node metastasis.一项针对伴有主动脉旁淋巴结转移的晚期胃癌的个体化综合治疗的试点研究。
BMC Gastroenterol. 2016 Jan 18;16:8. doi: 10.1186/s12876-016-0422-7.
8
Prophylactic lymph node dissection in patients with advanced gastric cancer promotes increased survival time.
Cancer. 1992 Jul 15;70(2):392-5. doi: 10.1002/1097-0142(19920715)70:2<392::aid-cncr2820700204>3.0.co;2-p.
9
[Multimodal therapy in patients with advanced gastric cancer].[晚期胃癌患者的多模式治疗]
MMW Fortschr Med. 2008 May 8;150(19):31-3.
10
Individualized adjuvant chemotherapy guided by chemosensitivity test sequential to extended surgery for advanced gastric cancer.针对进展期胃癌扩大手术后进行化疗敏感性试验指导下的个体化辅助化疗。
Anticancer Res. 2005 Sep-Oct;25(5):3453-9.

引用本文的文献

1
The optimal neoadjuvant chemotherapy regimen for locally advanced gastric and gastroesophageal junction adenocarcinoma: a systematic review and Bayesian network meta-analysis.局部晚期胃及胃食管结合部腺癌的最佳新辅助化疗方案:系统评价和贝叶斯网状meta 分析。
Eur J Med Res. 2022 Nov 9;27(1):239. doi: 10.1186/s40001-022-00878-7.
2
The postoperative component of MAGIC chemotherapy is associated with improved prognosis following surgical resection in gastric and gastrooesophageal junction adenocarcinomas.MAGIC化疗的术后部分与胃和胃食管交界腺癌手术切除后的预后改善相关。
Int J Surg Oncol. 2013;2013:781742. doi: 10.1155/2013/781742. Epub 2013 Sep 17.
3
R0 resection in the treatment of gastric cancer: room for improvement.
胃癌的 R0 切除术:仍有改进空间。
World J Gastroenterol. 2010 Jul 21;16(27):3358-70. doi: 10.3748/wjg.v16.i27.3358.
4
Treatment of multiple liver metastasis from gastric carcinoma.胃癌多发性肝转移的治疗
World J Surg Oncol. 2007 Jun 21;5:70. doi: 10.1186/1477-7819-5-70.
5
Perspectives of surgery and multimodality treatment in gastric carcinoma.胃癌的手术及多模式治疗前景
J Cancer Res Clin Oncol. 1993;119(7):384-94. doi: 10.1007/BF01218419.
6
Neoadjuvant chemotherapy for gastric cancer: update.
World J Surg. 1995 Jul-Aug;19(4):509-16. doi: 10.1007/BF00294711.
7
Protracted oral chemotherapy with fluorinated pyrimidines as an adjuvant to surgical treatment for stomach cancer.以氟嘧啶为辅助的延长口服化疗用于胃癌的手术治疗。
Ann Surg. 1977 Apr;185(4):462-6. doi: 10.1097/00000658-197704000-00016.